The company transitioned to a commercial-stage organization following the late December FDA approval of YARTEMLEA, the first and only treatment for TA-TMA. A strategic asset sale of zaltenibart to Novo Nordisk for up to $2.1 billion provided substantial non-dilutive capital, allowing for the full repayment of senior secured debt. YARTEMLEA's competitive positioning is driven by its upstream MASP-2 inhibition, which preserves immune function and avoids the 'black box' warnings and REMS programs require ...